A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy
Latest Information Update: 11 Apr 2019
At a glance
- Drugs House dust mite allergy immunotherapy subcutaneous HAL Allergy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors HAL Allergy
- 11 Apr 2019 Status changed from recruiting to completed.
- 11 Apr 2019 This trial has been completed in Portugal, according to European Clinical Trials Database.
- 04 Jul 2018 This trial was completed in Slovakia (2018-04-23), according to European Clinical Trials Database.